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Available online 26 August 2019Background: The dismal survival of glioblastoma (GBM) patients urgently calls for the development of new treat-
ments. Chimeric antigen receptor T (CAR-T) cells are an attractive strategy, but preclinical and clinical studies in
GBM have shown that heterogeneous expression of the antigens targeted so far causes tumor escape, highlight-
ing the need for the identification of new targets.We explored if B7-H3 is a valuable target for CAR-T cells inGBM.
Methods:We compared mRNA expression of antigens in GBM using TCGA data, and validated B7-H3 expression
by immunohistochemistry. We then tested the antitumor activity of B7-H3-redirected CAR-T cells against GBM
cell lines and patient-derived GBM neurospheres in vitro and in xenograft murine models.
Findings: B7-H3mRNA and protein are overexpressed inGBM relative to normal brain in all GBM subtypes. Of the
46 specimens analyzed by immunohistochemistry, 76% showed high B7-H3 expression, 22% had detectable, but
low B7-H3 expression and 2% were negative, as was normal brain. All 20 patient-derived neurospheres showed
ubiquitous B7-H3 expression. B7-H3-redirected CAR-T cells effectively targeted GBM cell lines and neurospheres
in vitro and in vivo. No significant differences were found between CD28 and 4-1BB co-stimulation, although
CD28-co-stimulated CAR-T cells released more inflammatory cytokines.
Interpretation:We demonstrated that B7-H3 is highly expressed in GBM specimens and neurospheres that con-
tain putative cancer stem cells, and that B7-H3-redirected CAR-T cells can effectively control tumor growth.
Therefore, B7-H3 represents a promising target in GBM.
Fund: Alex's Lemonade Stand Foundation; Il Fondo di Gio Onlus; National Cancer Institute; BurroughsWellcome
Fund.
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Glioblastoma (GBM) is an aggressive, malignant brain tumor with
abysmal survivorship [1]. Treatment typically consists of surgical resec-
tion followed by radiation therapy. The addition of temozolomide in-
creased the median survival (from 12·1 to 14·6 months) and 2-year
survival rate (from 10·4% to 26·5%) [2]. Observations of extensive vas-
cular proliferation in GBM led to the use of the VEGF-A inhibitingthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Research in context
Evidence before this study
Glioblastoma (GBM) is the most common primary adult brain
tumor and is characterized by poor outcome. Advancements in
cell-based immunotherapies opened the way for targeting GBM
with chimeric antigen receptor T (CAR-T) cells. However, the mo-
lecular heterogeneity of GBM, highlights the need for the identifi-
cation of novel targets. Moreover, cancer stem cells have been
shown to play a central role in tumor progression, treatment fail-
ure, and recurrence due to their proliferative capacity and resis-
tance to therapy, and thus targeting cancer stem cells in GBM is
important to eradicate the disease.
Added value of this study
We demonstrated in this report that B7-H3 is an attractive target
for CAR-T cells in GBM because it is highly expressed in 76% of
GBM specimens. Furthermore, B7-H3 is ubiquitously expressed
in patient-derived GBM neurospheres that are enriched in tumor
stem cells. B7-H3-specific CAR-T cells controlled tumor growth
in multiple in vitro and in vivomodels, highlighting the efficacy of
the proposed approach.
Implications of all available evidence
With the ability to deliver CAR-T cells intracranially, our approach
can potentially reduce tumor burden since B7-H3 is highly
expressed both within and across GBM tumors, prevent recur-
rence due to high B7-H3 expression on cancer stem cells, and
thus may extend the survival of patients with GBM.
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sion free survival and quality of life of the patients [3].
The systematicmolecular assessment of GBM indicates that receptor
tyrosine kinase (RTK) genes and the phosphatidylinositol-3-OH kinase
(PI3K), p53 and Rb pathways are dysregulated [4]. The identification
of these genetic events led to the development of various targeted ther-
apies, such as EGFR-targeting drugs (afatinib, erlotinib, antibody-drug
conjugates), and PI3K inhibitors (buparlisib). However, GBM is charac-
terized by great molecular heterogeneity, and different areas within a
single tumor can fall under different classification [5], which partially
explains the modest improvement of clinical outcome with targeted
therapies [6].
Chimeric antigen receptor (CAR) T cells are T lymphocytes geneti-
cally modified to express a synthetic receptor that produces activation
of the T cell machinery and co-stimulatory pathways upon ligation
with a cell surface antigen expressed by tumor cells [7]. CD19-
targeting CAR-T cells are FDA-approved for the treatment of
refractory/relapsed B-cell malignancies [8,9]. The activity of CAR-T
cells inhematologicmalignancies stimulated thedevelopmentof similar
strategies in solid tumors includingGBM. CAR-T cells targeting EGFRvIII,
HER2, and IL-13Rα2 have shown a favorable safety profile and some
clinical benefits in patients with GBM [10–12]. However, tumors recur
with evidence of immune escape due, at least in part, to antigen loss
[10–12]. New promising antigens characterized by high expression in
GBM, such as EphA2 and CSPG4, have been explored in preclinical stud-
ies [13,14], but tumor heterogeneity remains a concern highlighting the
need for the continuous identification of new targets. Here we report
that B7-H3, a member of the B7-family, is highly expressed in over 70%
of GBM specimens [15,16], and invariably expressed by patient-
derived GBM neurospheres (GBM-NS), while it is not detectable in the
normal brain. The expression of B7-H3 in GBM-NS is particularlyrelevant since these cells not only recapitulate themolecular properties
of the primary GBMwhen expanded in vitro or engrafted in immunode-
ficient mice [17,18], but are also considered to be enriched in putative
cancer stem cells (CSCs) [19]. B7-H3-specific CAR-T cells showed antitu-
mor activity both in vitro and in xenograft murine models with either
GBM cell lines or GBM-NS, indicating that targeting B7-H3 allows the
elimination of both differentiated tumor cells and CSCs.
2. Materials and methods
2.1. Analysis of the cancer genome atlas (TCGA) database
The PanCanmRNA normalized data (http://api.gdc.cancer.gov/data/
3586c0da-64d0-4b74-a449-5ff4d9136611) was downloaded, filtered
for primary tumors and log2 transformed. The gene expression for
CD276was then plotted by tumor type. GBM samples (primary tumors,
recurrent tumors and normal tissue) were also extracted from the
PanCan dataset and CD276, CSPG4, EPHA2, ERBB2, and IL13RA2 were
plotted by sample type. All analysis was performed in R.
2.2. GBM specimen, GBM-NS, tissue microarrays (TMAs), and cell lines
Patient GBM specimenswere obtained from the Department of Neu-
rosurgery (Istituto Neurologico Carlo Besta, Milan Italy) according to a
protocol approved by the local institutional review board and upon pa-
tients' informed consent. GBM diagnosis was determined according to
theWHO Classification [20]. GBM-NS were generated as previously de-
scribed [21]. GBM and normal brain formalin-fixed paraffin-embedded
(FFPE) TMAs were obtained from US BioMax (TMA #: GL801e,
BNC17011b, GLN241, RRID: SCR_004295). U-87 MG cells (RRID:
CVCL_0022) were obtained from ATCC, U-138 MG cells (RRID:
CVCL_0020) from DSMZ, and HL-60 cells (RRID: CVCL_0002) from
UNC's Tissue Culture Facility cell line repository which purchases its
lines from ATCC. U-87MG and U-138 MG cells were grown in Dulbecco
Modified Eagle Medium (DMEM) (Thermo Fisher Scientific) while HL-
60 cells were grown in RPMI 1640 (Thermo Fisher Scientific) supple-
mented with 10% fetal bovine serum (FBS) (Gemini Bio-Products), 1%
penicillin/streptomycin (Thermo Fisher Scientific), and 1% GlutaMAX™
(Thermo Fisher Scientific). Cell lines were phenotyped for B7-H3 ex-
pression using the 376.96 monoclonal antibody (mAb) followed by
APC-goat anti-mouse (BD Biosciences, RRID: AB_398465), or using the
B7-H3-BV421 mAb (Clone 7–517; BD Bioscience, RRID: AB_2739369)
[22]. SFG plasmid harboring green fluorescent protein and firefly lucif-
erase genes made in-house (SFG.GFP-FFLuc) was used to generate
dual GFP- and FFLuc-expressing cell lines. GBM cell lines and GBM-NS
were routinely tested to confirm the absence of mycoplasma (Lonza)
and for the expression of the targeted antigen by flow cytometry.
2.3. Immunohistochemistry (IHC)
Carnoy-fixedGBM specimens, and paraffin-embedded xenograft gli-
omas were processed as previously described [14]. The staining was
performed using the anti-B7-H3 mAb (1:200 dilution, AF1027, R&D
systems, RRID: AB_354546). Staining was detected using an anti-goat
biotin secondary mAb for two hour at room temperature, then a
streptavidin-HRP for one hour and the chromogen DAB/substrate re-
agent for the GBM specimens and VECTASTAIN® ABC HRP Kit for xeno-
graft gliomas. Slides were counterstained with hematoxylin (Sigma
Aldrich, Inc), dehydrated and mounted. A semiquantitative analysis of
B7-H3 expression was performed on 46 human GBM specimens by an
experienced pathologist (BP). The expression levels were scored as
b5% positive cells or 5–20% positive cells (− and +/−, respectively;
low expression); as 20–50% positive cells and N 50% positive cells (+
and ++, respectively; high expression). GBM and normal brain TMAs
were stained using the anti-B7-H3 mAb (AF1027, R&D Systems, RRID:
AB_354546) by the Translational Pathology Lab core facility and
35D. Nehama et al. / EBioMedicine 47 (2019) 33–43analyzed using the Aperio software. Total IHC score for each core in the
TMAswas calculated using Aperio Color Deconvolution Algorithm v9 as
follows: Score= (% area with IHC score 0) x 0+ (% area with IHC score
1+) x 1+ (% areawith IHC score 2+) x 2+ (% areawith IHC score 3+)
x 3. The score of each core was normalized to a positive control to com-
pare stains across slides.
2.4. Coculture experiments
The B7-H3.CAR cassettes were generated using the single chain var-
iable fragment (scFv) from the anti-B7-H3 376.96mAb [22]. The control
CD19.CAR was previously described [23]. CAR-T cells were generated
from healthy donor peripheral blood T cells (obtained from buffy
coats, Gulf Coast Regional Blood Center) as previously described [24].
B7-H3.CAR expression was assessed by incubating the CAR-T cells
with B7-H3-GFP [22]. CD19.CAR expression was assessed by incubation
with anti-CD19.CAR mAb [23]. To test the antitumor activity in vitro of
CAR-T cells, tumor cells were seeded at 1 × 105 cells/well in tissue
culture-treated plates (Corning) at either 1:5 or 1:10 effector-to-target
(E:T) ratio with the CAR-T cells. CAR-T cells were plated in cytokine-
freemedia for 24 h before being added to the tumor cells. In each exper-
iment, the percentage of CAR-T cells in each group was normalized to
the groupwith the lowest CAR expression using control T cells. Tomea-
sure cytokine release, the supernatant was collected 24 h after CAR-T
cell seeding. Cells were harvested non-enzymatically, using 480 μMeth-
ylenediaminetetraacetic acid (EDTA) (Thermo Fisher Scientific) in
phosphate buffered saline (PBS) (Thermo Fisher Scientific), and stained
with an anti-CD3mAb (clone SK7; BD Biosciences) to detect T cells, and
with mAbs specific for tumor markers to detect tumor cells, and sepa-
rately for viability using ZombieAqua viability dye (BioLegend). CAR-T
cells and tumor cells were quantified using CountBright™ Absolute
Counting Beads (Thermo Fisher Scientific). To identify the tumor cells
in coculture, we used an anti-AN2 mAb (Clone 1E6.4; Miltenyi Biotec,
RRID: AB_2651232) for U-87 MG and U-138 MG cells, and an anti-
CD33 mAb (Clone WM53; BD Biosciences, RRID: AB_2713912) for HL-
60 due to their uniform expression in their respective tumor cell lines
(Supplementary Fig. S1). In coculture experiments GBM tumor cell
lines were identified using the anti-AN2 mAb to avoid the potential
masking of the B7-H3 antigen by the interaction with the B7-H3.CAR
that may cause inaccurate enumeration of residual tumor cells. For co-
culture experiments with GBM-NS, cells were plated in tissue culture-
treated 24-well plates (Corning) at 1:5 E:T ratio with the CAR-T cells
in serum-free DMEM/F12 (Thermo Fisher Scientific)with B27™ supple-
ment (Thermo Fisher Scientific) [14]. The supernatant was collected
24 h after CAR-T cell seeding to measure cytokine release. Cells were
harvested after 1, 2, 3, or 5 days and stained with the anti-CD3 (Clone
REA613; Miltenyi Biotec, RRID: AB_2657063) and anti-B7-H3 (Clone
FM276; Miltenyi Biotec, RRID: AB_2661015) mAbs and analyzed by
flow cytometry. Interferon γ (IFNγ) and interleukin-2 (IL-2) levels in
24-h coculture supernatant were measured in duplicates using specific
enzyme-linked immunosorbent assay (ELISA) kits (R&D System) fol-
lowing themanufacturer's instructions. GBM-NS coculture experiments
were analyzed using MACSQuant® Analyzer (Miltenyi Biotec) and
FlowLogic V7.1 Software. All remaining flow cytometry experiments
were acquired using FACS Canto II (BD Bioscience), and analyzed
using the FlowJo software (Version 10.0). Carboxyfluorescein
succinimidyl ester (CFSE) staining was performed as previously de-
scribed [14].
2.5. Xenograft brain slice co-culture model
Hemicoronal brain slices (250 μm thick) from postnatal day 8 CD
Sprague Dawley rats (Charles River) were prepared using a vibratome
(Leica) and placed in 6-well plates with filtered transwell inserts
(Corning). The slices were maintained with 1 mL culture medium
(Neurobasal-A medium supplemented with 10% heat-inactivatedporcine serum, 5% heat-inactivated rat serum, 10 mM KCl, 10 mM (4-
(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 100 U/mL
Penicillin/Streptomycin, 1 mM Sodium Pyruvate, 1 mM L-Glutamine,
and 1 μM MK801) under the filter, incubating at 37 °C and 5% CO2.
HF2303 tumor neurospheres were obtained from Dr. Ana deCarvalho
and the Hermelin Brain Tumor Bank at Henry Ford Health System, De-
troit MI, USA. The neurospheres were infected using LV-GFP (RRID:
Addgene_25999) virus at 10 multiplicity of infection (MOI) with 5
μg/mL polybrene overnight and were maintained in NM medium
(DMEM/F12 supplemented with, 500 μg/mL bovine serum albusmin
(BSA), 12·5 μg/mL gentamycin, antibiotic-antimycotic, N-2 supple-
ment). U87-GFP-FFLuc cells were counted using Nexelcom Cellometer
Auto 2000 and prepared at 10,000,000 cells/mL. HF2303-GFP cells
counted using the hemacytometer were prepared at 200,000 cells/mL.
Each brain slice was plated with 5 μL of respective cell suspension
(50,000 U87-GFP-FFLuc cells or 10,000 HF2303-GFP cells). One
hundrend μL of media from eachwell was collected at 24 h after plating
for cytokine analysis.2.6. Xenograft mouse models
The antitumor activity of CAR-T cells was tested in nu/numice (An-
imal Studies Core Facility, UNC) according to an Institutional Animal
Care and Use Committee (IACUC) approved protocol. Female nu/nu
mice ages 6–10 weeks were injected with 1 × 105 U87-GFP-FFLuc
cells in 3 μL PBS intracranially at the following coordinates relative to
the bregma, corresponding to the caudate nucleus: 0·7mmposteriorly,
3 mm laterally to the right, and 3·5mmdeep. A week later, tumor bur-
denwas assessed using bioluminescence (BLI) measured by the IVIS Ki-
netic (Caliper LifeSciences), and 2 × 106 CAR-T cells in 5 μL PBS were
injected intratumorally. Tumor BLI was quantified weekly thereafter.
Mice were monitored every 2–3 days, and culled upon reaching hu-
mane end points in accordance with institutional guidelines. Overall
survival was assessed using Kaplan-Meier analysis. Explanted tumors
were dissociated usingHuman Tumor Dissociation Kit (Miltenyi Biotec)
as per the manufacturer's instructions. The antitumor activity against
GBM-NS was tested in congruence with a locally approved protocol
(Istituto Neurologico Carlo Besta, Milan, Italy) and in accordance to
the Italian Principle of Laboratory Animal Care (D. Lgs. 26/2014) and
European Communities Council Directives (86/609/EEC and 2010/63/
UE). Nude (CD1 (HO): CD1-Foxn1nu, from Charles River Laboratories,
Calco, Italy female mice ages six weeks were injected intracranially at
the coordinates described above with 1 × 105 GBM-NS cells in 2 μL
PBS and, 15 days later, with 2 × 106 CAR-T cells in 5 μL PBS
intratumorally (using the same stereotaxic coordinates used for the
tumor cell implantation). Mice were then monitored every 2–3 days
and sacrificed when showing neurological symptoms and/or reduced
body condition.2.7. Statistical analysis
Statistical significance of the difference of means between two
groups was assessed using a 2-tailed, nonparametric Mann-Whitney U
test. The difference of means between more than two groups was
assessed using one-way or two-way ANOVA with Bonferroni's post-
test correction. The difference in overall survival in Kaplan-Meier curves
was determined using the log-rank Mantel-Cox test. All statistical anal-
yses were performed in GraphPrism (Version 5.03).2.8. Data availability statement
The data that support the findings in this study are available upon
request.
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3.1. B7-H3 is expressed in GBM specimens
To assess the expression profile of B7-H3 in GBM, we first evaluated
the B7-H3 mRNA expression (Gene name: CD276) in The Cancer Ge-
nome Atlas (TCGA) dataset. GBM showed relatively high B7-H3 expres-
sion,with about 77% of samples lying above themean B7-H3 expression
of all TCGA tumors (Supplementary Fig. S2). Importantly, B7-H3 was
found expressed at similarly elevated levels in primary (“P”) and recur-
rent (“R”) GBM relative to normal (“N”) brain tissue (Fig. 1a). In addi-
tion, B7-H3 mRNA levels also had the smallest variance as compared
to the other molecules such as CSPG4, EPHA2, ERBB2, and IL13RA2 that
are targeted with CAR-T cells (Fig. 1a). Since mRNA levels do not neces-
sarily directly predict protein expression, we evaluated the B7-H3Fig. 1. B7-H3 expression in GBM. (a) Normalized mRNA levels of CD276 (B7-H3), CSPG4,
EPHA2, ERBB2, and IL13RA2 in adjacent normal (“N”), primary GBM (“P”), and recurrent
GBM (“R”) samples in TCGA. Each point represents a different TCGA sample. (b-e).
Representative examples of B7-H3 immunostaining in classical (b), proneural (c),
mesenchymal GBM (d), and a rare case of giant cell GBM (e). (f) Representative B7-H3
immunostaining of commercially available GBM tissue arrays and normal brain. (g) B7-
H3 expression scores of the tissue microarrays of GBM (n = 32) and normal brain cores
(n = 69) quantified via color deconvolution algorithm. Statistical analysis of difference
in means was performed using two-tailed nonparametric Mann-Whitney U test (***p b
0·0001). Scale bar (b)-(e), 50 μm. Scale bar (f), 400 μm.protein expression by immunohistochemistry in a cohort of 46 GBM
specimens previously studied for the expression of CSPG4 [14]. We ob-
served a diffuse positivity of B7-H3 expression, with 76% (35/46) of the
specimens displaying a strong immunoreactivity for B7-H3, and 22%
(10/46) showing detectable but low expression (Fig. 1b-e and
Table 1). B7-H3 was not detected in one specimen. B7-H3 expression
was mainly located into the plasma membrane of tumor cells. Among
GBM with high B7-H3 expression, 41% were assigned to the classical
subtype, 34% to the mesenchymal subtype and 25% to the proneural
subtype (Table 1). Of note, tumor cells recruited in the vicinity of
blood vessels, as well as adjacent normal-infiltrating tumor cells, were
intensely positive for B7-H3 (Supplementary Fig. S3). To further validate
these results, we also stained commercially available human tissue mi-
croarrays containing GBM specimens (n = 32) and normal brain (n =
69) spanning various central nervous system structures as well as the
optic nerve. All GBM samples overexpressed B7-H3 relatively to normal
brain samples (Fig. 1f,g).Table 1







BT137 + PN NE
BT140 + MES NE
BT150 + CLAS NE
BT202 + MES NE
BT205 + PN 98.0
BT211 + MES NE
BT219 + MES NE
BT235 + CLAS NE
BT241 + NA NE
BT245 + PN NE
BT248 + NA NE
BT302 + MES 99.0
BT308 + PN 98.0
BT328 + MES 92.3
BT337 + PN NE
BT347 + NA NE
BT379 + CLAS 94.8
BT417 + CLAS 98.0
BT422 + CLAS 98.4
BT423 + CLAS 94.6
BT462 + CLAS 99.8
BT482 + MES 99.9
BT483 + PN 98.0
BT513 + MES NE
BT517 + CLAS 97.7
BT138 ++ CLAS NE
BT168 ++ MES 99.9
BT175 ++ NA NE
BT275 ++ CLAS 97.1
BT283 ++ CLAS NE
BT261 ++ CLAS NE
BT358 ++ MES 92.1
BT373 ++ PN 89.0
BT480 ++ MES NE
BT500 ++ CLAS NE
BT487 +/− MES 96.4
BT326 +/− PN 90.1
BT273 +/− CLAS 97.8
BT299 +/− PN 95.5
BT155 +/− CLAS NE
BT209 +/− PN NE
BT206 +/− CLAS NE
BT334 +/− CLAS NE
BT274 +/− PN NE
BT279 +/− CLAS NE
BT157 − MES NE
Abbreviations: GBM-NS: glioblastoma-neurospheres; PN: proneural; CLAS: classical;MES:
mesenchymal; NA: not available; NE: not evaluated. A total of 20 GBM-NS were assessed
by flow cytometry for B7-H3 expression, which is indicated as percentage of positive cells.
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We generated B7-H3-redirected CAR (B7-H3.CAR) T cells encoding
either CD28 or 4-1BB endodomains (B7-H3.CD28 and B7-H3.41BB, re-
spectively) [22], and CD19-redirected CAR (CD19.CD28) T cells [23] as
control through retroviral transduction of activated T cells from healthy
donors (Fig. 2a, b). CAR expression was assessed to be 93%± 3%, 62%±
14%, and 51% ± 8% in CD19.CD28, B7-H3.CD28, and B7-H3.41BB CAR-T
cells, respectively. CAR-T cells were then tested for antitumor activity
against the U-87 MG and U-138 MG human GBM tumor cell lines,
which express B7-H3, while the B7-H3-negative HL-60 leukemia cell
line served as a negative control (Fig. 2c). B7-H3.CAR-T cells showed
complete or near complete elimination of U-87 MG and U-138 MG
cells five days after seeding at 1:5 and 1:10 E:T ratios, as measured by
the number of tumor cells remaining, with no statistically significant
difference between B7-H3.CD28 and B7-H3.41BB CAR-T cells (vs. U-87
MG: 2311 ± 3639 and 1483 ± 927 at 1:5 E:T, 14908 ± 18,548 and
32,345 ± 27,580 at 1:10 E:T; vs. U-138 MG: 384 ± 338 and 1260 ±
1175 at 1:5 E:T, 7376 ± 5402 and 8835 ± 5716 at 1:10 E:T, tumorFig. 2. B7-H3.CAR-T cells target humanGBM cell lines in vitro. (a) Representative plots showing
flowcytometry. Expression is represented relative to non-transduced control T cells (cT). (b) Su
H3 in U-87MG, U-138MG, and HL-60 cells stainedwith the 376.96mAb and APC goat anti-mou
goat anti-mouse alone. (d) Representative flow cytometry plots of CAR-T cells (CD3+) cocultur
or 1:10 effector-to-target (E:T) ratios for five days. (e) The number of remaining U-87MG, U-13
were calculated using counting beads. Data representmean± SD (n=3–4 donors). Each dono
ANOVA with Bonferroni's post-test correction (*p b 0·05, **p b 0·01).cells remaining against B7-H3.CD28 and B7-H3.41BB CAR-T cells, re-
spectively). There was no evidence of killing in wells seeded with
CD19.CD28 CAR-T cells or control non-transduced T cells (cT) and in
wells seeded with HL-60 cells (Fig. 2d, e). We measured cytokine re-
lease by CAR-T cells in the coculture supernatant after 24 h and CAR-T
cell proliferation in response to antigen stimulation. The effector cyto-
kines IFNγ and IL-2 were detected in the supernatant only when B7-
H3.CAR-T cells were cocultured with U-87 MG or U-138 MG cells,
with B7-H3.CD28 CAR-T cells showing higher cytokine release as com-
pared to B7-H3.41BB CAR-T cells (vs. U-87 MG: 791 ± 607 and 96 ±
110 IFNγ, 541 ± 220 and 167 ± 139 IL-2; vs. U-138 MG: 131 ± 140
and 0 ± 0 IFNγ, 193 ± 74 and 26 ± 30 IL-2, pg/mL/2 × 104 B7-H3.
CD28 and B7-H3.41BB CAR-T cells, respectively) (Fig. 3a, b). To examine
the proliferative capacity of B7-H3.CAR-T cells in response to antigen
stimulation, we labeled the T cells with CFSE and cocultured them
with U-87 MG, U-138 MG, or HL-60 cells at a 1:1 E:T ratio. After five
days in coculture, B7-H3.CAR-T cells proliferated only in response to
U-87 MG and U-138 MG cells, with no statistical difference seen be-
tween B7-H3.CD28 and B7-H3.41BB CAR-T cells (vs. U-87 MG: 97% ±
3% and 97% ± 1%; vs. U-138 MG: 97% ± 2% and 93% ± 5%,the CAR expression in CD19.CD28, B7-H3.CD28 and B7-H3.41BB CAR-T cells as assessed by
mmary of CAR expression. Data representmean±SD (n=6donors). (c) Expression of B7-
se and assessed by flow cytometry. Expression is represented relative to stainingwith APC
edwith U-87MG cells (CSPG4+), U-138MG cells (CSPG4+), or HL-60 cells (CD33+) at 1:5
8MG, or HL-60 cells in 1:5 and 1:10 E:T coculture experiments in (d). Tumor cell numbers
r was tested once for each experiment. Difference inmeanswas assessed through one-way
38 D. Nehama et al. / EBioMedicine 47 (2019) 33–43CFSE-dilutedB7-H3.CD28andB7-H3.41BBCAR-T cells, respectively).No
proliferationwas observed in CD19.CD28 CAR-T and cT cells (Fig. 3c, d).
The antitumor activity of B7-H3.CAR-T cells was then tested in a
xenograft murine model. We first generated U-87 MG cells stably ex-
pressing GFP-FFLuc (U87-GFP-FFLuc) (Supplementary Fig. S1). U87-
GFP-FFLuc were then injected intracranially into the caudate nucleus
of nu/nu mice. One week later, mice were treated intratumorally with
CD19.CD28, B7-H3.CD28 or B7-H3.41BB CAR-T cells. Tumor growth
wasmonitored by BLI (Fig. 4a). In each experiment, micewere assigned
a treatment such that the pre-treatment tumor BLI distribution was
comparable in each treatment group. Among mice with initial tumor
burden b1 × 108 p/s/cm2/sr total flux, sustained tumor regression wasFig. 3. B7-H3.CAR-T cells release effector cytokines and proliferate in response to B7-H3+GBM c
coculture of CAR-T cells or cTs with U-87MG, U-138MG, or HL-60 cells at 1:5 E:T ratio. Data rep
ANOVA with Bonferroni's post-test correction (*p b 0·05, ***p b 0·0001). (c) Representative CF
MG, or HL-60 cells for five days. The percent of CFSE dilutionwasmeasured relative to CFSE-labe
± SD (n = 5–6 donors). Each donor was tested once for each experiment. Difference in mea
0·0001).seen in 86% (6/7) and 100% (5/5) of those treated with B7-H3.CD28
CAR-T cells or B7-H3.41BB CAR-T cells, respectively (Fig. 4b, c). B7-H3.
CAR-T cell treatment conferred a significant and prolonged survival
benefit, with no significant difference between B7-H3.CD28 (6 of 11
mice survive N120 days) and B7-H3.41BB (6 of 10 mice survive
N120 days) CAR-T cells. (Fig. 4d). In mice with tumor recurrence ob-
served after day 40, harvested tumors from mice treated with B7-H3.
CAR-T cells revealed retention of the B7-H3 expression in tumor cells
(Fig. 4e) indicating that tumor recurrence is not caused by antigen
loss. No treatment-related adverse effects were observed. We could
not assess the effects of B7-H3.CAR-T cells in mice engrafted with U-
138MG cells because this tumor cell line had inconsistent engraftment,ell lines. (a-b) Quantification of IFNγ (a) and IL-2 (b) by ELISA in the supernatant 24 h after
resent mean± SD (n=5–6 donors). Difference inmeans was assessed through one-way
SE dilution of CFSE-labeled CAR-T cells cocultured at a 1:1 E:T ratio with U-87 MG, U-138
led CAR-T cells cultured alone. (d) Summary of CFSE-dilution assays. Data representmean
ns was assessed through one-way ANOVA with Bonferroni's post-test correction (***p b
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40 D. Nehama et al. / EBioMedicine 47 (2019) 33–43andwhen engraftedwas characterized by very slow tumor growthwith
nomorbidity even months after engraftment. To further prove that B7-
H3.CAR-T cells can target tumor cells in situ, we developed a xenograft
rat brain slice coculture model in which U87-GFP-FFLuc or GBM-NS-
GFP cells are seeded onto rat brain slices and treated one day later
with either CD19.CAR-T cells, B7-H3.CAR-T cells, or no cells (Fig. 4f, g).
Cytokine quantification of supernatant 24 h after CAR-T cell treatment
reveals IFNγ and IL-2 release only in the presence of B7-H3.CAR-T
cells, with B7-H3.CD28 CAR-T cells releasing more IFNγ and IL-2 in 2
out of 3 U87-GFP-FFLuc-seeded brain slices and more IL-2 in 2 out of 2
GBM-NS-GFP-seeded brain slices. Similar levels of IFNγ were released
by B7-H3.CD28 and B7-H3.41BB CAR-T cells in all GBM-NS-GFP-
seeded slices (vs. U87-GFP-FFLuc: 882 ± 497 and 469 ± 81 IFNγ, 266
± 122 and 111 ± 14 IL-2 pg/mL/2.5 × 104; vs. GBM-NS: 254 ± 70 and
213 ± 49 IFNγ, 95 ± 10 and 16 ± 9 IL-2, pg/mL/6.3 × 103 B7-H3.
CD28 and B7-H3.41BB CAR-T cells, respectively) (Fig. 4h, i).
3.3. B7-H3.CAR-T cells target GBM-NS in vitro and in vivo
Since GBM established tumor cell lines do not fully recapitulate the
molecular subtypes of human GBM and do not mimic human CSCs, we
sought to test B7-H3.CAR-T cells against patient-derived GBM-NS [25].
We measured the expression of B7-H3 in 20 GBM-NS representative
of the most common GBMmolecular subtypes. We found high expres-
sion levels of B7-H3 (ranging from 89% to 100% of cells) in all GBM-
NS, independently of their molecular subtype (Fig. 5a, b and Table 1).
We tested the antitumor activity of B7-H3.CAR-T cells against five rep-
resentative GBM-NS. The killing ability of B7-H3.CAR-T cells was evalu-
ated by flow cytometry in a coculture assay at different time points
using 1:5 E:T ratio. B7-H3.CAR-T cells encoding CD28 showed promi-
nent antitumor efficacy already at 24 h as compared to those encoding
4-1BB. However, at 48 h B7-H3.CD28 and B7-H3.41BB CAR-T cells
equally eliminated GBM-NS from the culture (residual GBM-NS b 2%).
In contrast, GBM-NS continued to grow in the presence of CD19.CD28
CAR-T cells (Fig. 5c). The Th1 cytokine profile in the supernatant in re-
sponse to GBM-NS revealed no difference between the levels of IFNγ re-
leased by B7-H3.CD28 and B7-H3.41BB (965 ± 161 and 921 ±
828 pg/mL/1 × 105 B7-H3.CD28 and B7-H3.41BB CAR-T cells, respec-
tively). However, the elevated IFNγ release by B7-H3.41BB CAR-T cells
in 2 out of 5 GBM-NS tested correlates with the upregulation of PD-L1
in GBM-NS upon exposure to IFNγ, as we have previously reported
(Fig. 5d) [14]. Nevertheless, B7-H3.CAR-T cells encoding CD28 released
higher amount of IL-2, consistentwith the in vitro studieswith U-87MG
and U-138 MG cell lines (641 ± 175 and 407 ± 116 pg/mL/1 × 105 B7-
H3.CD28 and B7-H3.41BB CAR-T cells, respectively) (Fig. 5e).
To test in vivo the antitumor activity of B7-H3.CAR-T cells against
GBM-NS, nu/numice were implanted with GBM-NS into the brain, and
CAR-T cells or control T cells were injected intratumorally 15 days
later (Fig. 5f). B7-H3.CAR-T cells encoding either CD28 or 4-1BB equally
controlled the tumor growth and prolonged the survival in 50% of the
treated mice as compared to mice treated with control T cells (3 of 6
mice for both B7-H3.CD28 and B7-H3.41BB-treated groups) (Fig. 5g).
Morphological analyses performed on explanted brains showed high
cellularity in control xenograft gliomas. On the contrary, in B7-H3.
CAR-T cell-treated xenograft gliomas the architecture was disrupted
by large damaged and necrotic areas (Fig. 5h, i). As observed in the
tumor model with GBM tumor cell line, recurrent tumors harvestedFig. 4. B7-H3.CAR-T cells control the growth of humanGBMcell lines in vivo. (a) Schemaof the x
GFP-FFLucGBMcells (1× 105 cells) were inoculated into the caudate nucleus and tumor growth
injected intratumorally oneweek after tumor inoculation. (b) Representative images of tumor B
=9–11mice/group across 3 donors of T cells). (d) Kaplan-Meier analysis of overall survival of th
b 0·0001). (e) Representative flow cytometry plots showing the expression of GFP and B7-H3
setup of xenograft rat brain slice coculture model. (g) Representative images demonstrating U
(h) and IL-2 (i) by ELISA in the supernatant 24 h after coculture of CAR-T cells with U87-GFP-FFL
against U87-GFP-FFLuc cells or oneGBM-NS-GFP line on 1–3 different rat brain slices. Each dono
ANOVA with Bonferroni's post-test correction (**p b 0·01).from mice treated with B7-H3.CAR-T cells retained B7-H3 expression
in tumor cells (Fig. 5i).
4. Discussion
One of the greatest barriers to developing effective immune thera-
pies for GBM is the heterogeneity of antigen expression within and
across tumors, which highlights the need of the identification of novel
targets. B7-H3 is a promising therapeutic target in GBM and other
solid tumors due to its high expression in tumor cells and low expres-
sion in normal tissues [16,22]. In this report, we confirmed that B7-H3
is highly expressed in GBM and provided comprehensive evidence
that GBM can be effectively targeted using B7-H3-specific CAR-T cells.
Furthermore, we found that B7-H3 expression is highly conserved in
patient-derived GBM-NS supporting the potential of the proposed strat-
egy to eradicate tumor cells with high tumor regenerative capacity.
Clinical trials of CAR-T cells in GBM patients have demonstrated
tumor regression after either systemic or intracranial delivery routes
[10–12]. Nonetheless, these trials also highlighted how tumor antigen
escape due to the heterogeneous expression of the antigens hinders
the durability of clinical responses. A bioactivity and safety study of
IL13Rα2-targeted CD8+ CAR-T cells by Brown et al. documented recur-
rence of IL13Rα2-negative tumors [10,26]. Similarly, O'Rourke and col-
leagues described recurrence of antigen-negative tumors in patients
with GBM treated with EGFRvIII-directed CAR-T cells [11]. The identifi-
cation of antigens that are invariably expressed by tumor cells, but not
by the counterpart normal cells remains a high priority to target solid
tumors, including GBM, with CAR-T cells. We have previously reported
that targeting CSPG4 in GBM partially addresses the issue, because
CSPG4 is highly expressed in 67% of the GBM specimens we tested,
and is also expressed in tumor-associated vessels, but not in normal ce-
rebral vessels and normal brain [14]. Furthermore, we observed that
CSPG4 expression can be induced by TNFα released by residentmicrog-
lia, and potentially by TNFα secreted by CAR-T cells upon activation
[14]. In this manuscript, we report that B7-H3 is also highly expressed
in 76% of GBM, but not in normal brain tissue, and that targeting B7-
H3 via CAR-T cells promotes antitumor activity both in vitro and in xe-
nograft models highlighting the clinical relevance of B7-H3 as a molec-
ular target in GBM. However, as previously observed for CSPG4 [14], a
third of the GBM specimens analyzed show low expression of B7-H3,
and this level of expressionmay be insufficient to promote effective kill-
ing by CAR-T cells as we have recently reported [22]. Nevertheless, the
data presented in this report demonstrate that B7-H3 is almost invari-
ably expressed in patient-derived GBM-NS spanning all molecular
GBM subtypes. Furthermore, GBM-NS are effectively targeted by B7-
H3-redirected CAR-T cells both in vitro and in vivo. GBM-NS are gener-
ated from human GBM samples using the same growth factors
employed for neural stem cells and are enriched in putative CSCs [19].
Since several lines of evidence indicate that CSCs have a critical role in
causing tumor recurrence [18,27,28], effectively targeting these cells
with B7-H3.CAR-T cells offers greater potential to control tumor recur-
rence even if some differentiated tumor cells may not be eliminated be-
cause they express B7-H3 at low levels. Due to its high expression in
GBM specimens and GBM-NS and lack of expression on normal brain,
B7-H3 may thus represent an ideal target in a high proportion of pa-
tients as single antigen or in combination with other validated targets
to offer CAR-T cells to the majority of patients with GBM [32–34].enograftmurinemodel used to test the antitumor effects of B7-H3.CAR-T cells in vivo. U87-
wasmonitoredweekly by bioluminescence (BLI) imaging. CAR-T cells (2× 106 cells)were
LI. (c) Log-transformed BLI values showing the kinetics of tumor growth of eachmouse (n
e treatedmice. Statistical analysiswas performed using theMantel-Cox log rank test (***p
in U87-GFP-FFLuc tumors explanted from mice treated with CAR-T cells. (f) Experimental
87-GFP-FFLuc and GBM-NS-GFP cells seeded on rat brain slice. (h,i) Quantification of IFNγ
uc cells or GBM-NS-GFP at 1:2 E:T ratio on rat brain slides. Data represent one donor tested
rwas tested once for each experiment. Difference inmeanswas assessed through one-way
41D. Nehama et al. / EBioMedicine 47 (2019) 33–43Occurrence of cerebral edema and cytokine release syndrome has
been attributed to CAR-T cells in hematologicmalignancies [29]. Clinical
studies of CAR-T cells in GBMpatients have shown a relatively favorable
safety profile, with no dose-limiting toxicities seen for HER2- andFig. 5. B7-H3.CAR-T cells control the growth of human GBM-NS in vitro and in vivo. (a) Represen
assessed by flow cytometry. GBM-NS were subdivided by molecular subtypes (MES: mesenchy
with GBM-NS at 1:5 E:T ratio and residual tumor cells (B7-H3+)were quantified by flow cytom
against five GBM-NS. Difference in means was assessed through two-way ANOVA with Bon
(e) release by B7-H3.CAR-T cells and CD19.CAR-T cells in the supernatant collected 24 h a
compared to BT308-NS, BT302-NS and BT273-NS [14]. Data represent the average of two don
one-way ANOVA with Bonferroni's post-test correction (*p b 0·05). (f) Schema of the xenogr
GBM-NS. GBM-NS (1 × 105 cells) were inoculated into the caudate nucleus and CAR-T cells f
Meier curves showing the overall survival of the treated mice (n = 6 mice/group). Overall sur
Tissue morphology assessed by hematoxylin and eosin staining and B7-H3 expression assess
(h) Gliomas collected from mice treated with CD19.CAR-T cells show high cellularity and high
necrotic zones with fibrotic areas (marked by asterisks) and disrupted tumor architecture. D
CAR-T cell donor was tested once for each experiment.EGFRvIII-redirected CAR-T cells [11,12], andmanageable grade 3 events
(headache, neurologic deficits) in patients treated with high dose anti-
IL13Rα2 CAR-T cells intracranially [10,26]. We have previously demon-
strated that B7-H3 is not expressed in normal brain [22]. Furthermore,tative flow plots and (b) summary plots showing B7-H3 expression in human GBM-NS as
mal, n= 6; PN: proneural, n = 6; CLAS: classical, n= 8). (c) CAR-T cells were cocultured
etry at different time points. Data represent the average of two donors of CAR-T cells tested
ferroni's post-test correction (***p b 0·0001). (d,e) Quantification of IFNγ (d) and IL-2
fter coculture with GBM-NS. BT166-NS and BT462-NS released higher levels of IFNγ
ors of CAR-T cells tested against five GBM-NS. Difference in means was assessed through
aft murine experimental model used to test the antitumor effects of CAR-T cells against
rom one donor (2 × 106 cells) were injected intratumorally two week later. (g) Kaplan-
vival comparison was measured using the Mantel-Cox log rank test (***p b 0·0001). (h,i)
ed by immunohistochemistry of xenograft gliomas collected from tumor-bearing mice.
B7-H3 expression. (i) Gliomas collected from mice treated with B7-H3.CAR-T cells show
elimited area shows dense cellularity at the borders of necrosis. Scale bar, 100 μm. Each
42 D. Nehama et al. / EBioMedicine 47 (2019) 33–43in a clinical study in which the 131I-conjugated B7-H3 Abwas adminis-
tered intracranially to patientswithmetastatic neuroblastoma, no toxic-
ity was encountered [30]. The B7-H3.CAR we have developed shows
cross-reactivity to murine B7-H3, but no toxicity was observed in mice
either immunodeficient or immunocompetent when B7-H3.CAR-T
cells were infused systemically [22].. In this report, B7-H3.CAR-T cells
injected directly intracranially in murine models of GBM also did not
cause toxicity attributable to on target off tumor recognition of B7-H3.
These data suggest that on-target but off-tumor toxicity may not occur
in human subjects.
We observed only limited differences in the antitumor activity of B7-
H3.CAR-T cells encoding either CD28 or 4-1BB co-stimulatory domains
both in vitro and in vivo. As previously reported [31], we observed that
CD28 co-stimulation provides faster antitumor effects as compared to
4-1BB co-stimulation, but this did not translate into enhanced antitu-
mor activity in the experimental conditions we have used in vitro and
in vivo. The intratumor delivery route of the CAR-T cells may confer im-
mediate exposure of the CAR-T cells to tumor cells and overcome the
difference in cytokine release we observed in vitro between CD28 and
4-1BB co-stimulation, leading to equivalent antitumor efficacy in vivo.
Of note, nearly all the mice with large initial tumor burden failed treat-
ment irrespective of the provided co-stimulation, highlighting the im-
portance of additional studies aimed at enhancing the persistence of
CAR-T cells within the tumor environment to eradicate large tumors
or the need of early detection of tumor recurrence and early treatment.
In conclusion, our study shows that B7-H3 is an attractive target in
GBM since it is highly expressed in 76% of the GBM specimens tested
across all subtypes and is invariably expressed in GBM-NS that contain
CSCs, while it is not detectable in normal brain. B7-H3-redirected
CAR-T cells control tumor growth in multiple human GBM models,
and B7-H3 expression is retained at tumor recurrence indicating that
strategies aimed at enhancing the CAR-T cell delivery and persistence
within the tumor may further increase the efficacy profile of B7-H3-
redirected CAR-T cells in GBM.
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